Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility (Q38102595)

2

1 reference

28 August 2017

Efstathios Papadakis

3

1 reference

28 August 2017

Christos Vosnakis

4

1 reference

28 August 2017

Panagiotis Chatzis

5

1 reference

28 August 2017

Ilias Katsikis

https://scigraph.springernature.com/pub.10.1007/s12020-013-9971-5

6

1 reference

28 August 2017

27 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

44

1 reference

28 August 2017

583-590

1 reference

28 August 2017

3

1 reference

28 August 2017

0 references

cites work

Metformin for the treatment of the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Development of polycystic ovary syndrome: involvement of genetic and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

The pathophysiology of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Molecular mechanisms of insulin resistance in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Treatment options for polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

New concepts in human sperm-zona pellucida interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Exercise for the treatment and management of overweight women with polycystic ovary syndrome: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

The optimal diet for women with polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Polycystic ovary syndrome (PCOS) and other androgen excess-related conditions: can changes in dietary intake make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Role of diet in the treatment of polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Effects of exercise and nutritional counseling in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Exercise therapy in polycystic ovary syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Polycystic ovarian syndrome: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

An retrospective audit of patients with polycystic ovary syndrome: the effects of a reduced glycaemic load diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9971-5

Current trends in the treatment of polycystic ovary syndrome with desire for children

21 January 2018

1 reference

12 December 2020

The decrease in luteinizing hormone secretion in response to weight reduction is inversely related to the severity of insulin resistance in overweight women.

1 reference

12 December 2020

The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study.

1 reference

12 December 2020

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

1 reference

12 December 2020

Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.

1 reference

12 December 2020

Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome

1 reference

12 December 2020

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

1 reference

12 December 2020

Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome

1 reference

12 December 2020

Polycystic ovary syndrome

1 reference

12 December 2020

Medical therapy for obesity--current status and future hopes

1 reference

12 December 2020

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women

1 reference

12 December 2020

Lifestyle changes in women with polycystic ovary syndrome

1 reference

12 December 2020

The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study

1 reference

12 December 2020